TY - JOUR
T1 - Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer
AU - Kuijpers, Chantal C H J
AU - Moelans, Cathy B.
AU - Van Slooten, Henk Jan
AU - Horstman, Anja
AU - Hinrichs, John W J
AU - Al-Janabi, Shaimaa
AU - Van Diest, Paul J.
AU - Jiwa, Mehdi
PY - 2013/12/4
Y1 - 2013/12/4
N2 - Background: HER-2 is a prognostic and predictive marker, but as yet no technique is perfectly able to identify patients likely to benefit from HER-2 targeted therapies. We aimed to prospectively assess the added value of first-line co-testing by IHC, and multiplex ligation-dependent probe amplification (MLPA) and chromogenic in situ hybridization (CISH). Methods: As local validation, HER-2 MLPA and CISH were compared in 99 breast cancers. Next, we reviewed 937 invasive breast cancers, from 4 Dutch pathology laboratories, that were prospectively assessed for HER-2 by IHC and MLPA (and CISH in selected cases). Results: The validation study demonstrated 100% concordance between CISH and MLPA, if both methods were assessable and conclusive (81.8% of cases). Significant variation regarding percentages IHC 0/1+ and 2+ cases was observed between the laboratories (p
AB - Background: HER-2 is a prognostic and predictive marker, but as yet no technique is perfectly able to identify patients likely to benefit from HER-2 targeted therapies. We aimed to prospectively assess the added value of first-line co-testing by IHC, and multiplex ligation-dependent probe amplification (MLPA) and chromogenic in situ hybridization (CISH). Methods: As local validation, HER-2 MLPA and CISH were compared in 99 breast cancers. Next, we reviewed 937 invasive breast cancers, from 4 Dutch pathology laboratories, that were prospectively assessed for HER-2 by IHC and MLPA (and CISH in selected cases). Results: The validation study demonstrated 100% concordance between CISH and MLPA, if both methods were assessable and conclusive (81.8% of cases). Significant variation regarding percentages IHC 0/1+ and 2+ cases was observed between the laboratories (p
UR - http://www.scopus.com/inward/record.url?scp=84891893438&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891893438&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0082018
DO - 10.1371/journal.pone.0082018
M3 - Article
C2 - 24324739
AN - SCOPUS:84891893438
SN - 1932-6203
VL - 8
JO - PLoS One
JF - PLoS One
IS - 12
M1 - e82018
ER -